A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Abituzumab (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PERSEUS
  • Sponsors EMD Pharmaceuticals; EMD Serono; Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Feb 2016 Primary endpoint has not been met. (Progression Free Survival (PFS) Time), as per an article published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 02 Feb 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top